Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers DOI Open Access
Lindsey Carlsen, Kelsey E. Huntington, Wafik S. El‐Deiry

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(4), P. 1028 - 1028

Published: Feb. 17, 2022

Though early-stage colorectal cancer has a high 5 year survival rate of 65–92% depending on the specific stage, this probability drops to 13% after metastasizes. Frontline treatments for such as chemotherapy and radiation often produce dose-limiting toxicities in patients acquired resistance cells. Additional targeted are needed improve patient outcomes quality life. Immunotherapy involves treatment with peptides, cells, antibodies, viruses, or small molecules engage train immune system kill Preclinical clinical investigations immunotherapy including checkpoint blockade, adoptive cell therapy, monoclonal oncolytic anti-cancer vaccines, modulators have been promising, but demonstrate limitations proficient mismatch repair enzymes. In review, we discuss preclinical studies investigating predictive biomarkers response these treatments. We also consider open questions optimal combination maximize efficacy, minimize toxicity, prevent approaches sensitize repair-proficient immunotherapy.

Language: Английский

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial DOI
Yasutoshi Kuboki, Marwan Fakih, John H. Strickler

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(1), P. 265 - 270

Published: Jan. 1, 2024

Language: Английский

Citations

34
Cutaneous adverse effects of targeted therapies DOI
James B. Macdonald,

Brooke Macdonald,

Loren E. Golitz

et al.

Journal of the American Academy of Dermatology, Journal Year: 2015, Volume and Issue: 72(2), P. 221 - 236

Published: Jan. 12, 2015

Language: Английский

Citations

171
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors DOI Open Access

Émmanuelle Vigarios,

Joel B. Epstein, V. Sibaud

et al.

Supportive Care in Cancer, Journal Year: 2017, Volume and Issue: 25(5), P. 1713 - 1739

Published: Feb. 22, 2017

Language: Английский

Citations

164
Treatment of Renal Fibrosis—Turning Challenges into Opportunities DOI
Barbara M. Klinkhammer, Roel Goldschmeding, Jürgen Floege

et al.

Advances in Chronic Kidney Disease, Journal Year: 2017, Volume and Issue: 24(2), P. 117 - 129

Published: March 1, 2017

Language: Английский

Citations

137
TRPM7, Magnesium, and Signaling DOI Open Access
Zhiguo Zou, Francisco J. Rios, Augusto C. Montezano

et al.

International Journal of Molecular Sciences, Journal Year: 2019, Volume and Issue: 20(8), P. 1877 - 1877

Published: April 16, 2019

The transient receptor potential melastatin-subfamily member 7 (TRPM7) is a ubiquitously expressed chanzyme that possesses an ion channel permeable to the divalent cations Mg2+, Ca2+, and Zn2+, α-kinase phosphorylates downstream substrates. TRPM7 its homologue TRPM6 have been implicated in variety of cellular functions critically associated with intracellular signaling, including tyrosine kinase (RTK)-mediated pathways. Emerging evidence indicates growth factors, such as EGF VEGF, signal through their RTKs, which regulate activity TRPM7. primarily epithelial-associated channel, while more ubiquitous. In this review we focus on association signaling. We also highlight how interplay between TRPM7, Mg2+ signaling kinases influences cell function physiological pathological conditions, cancer preeclampsia.

Language: Английский

Citations

128
Managing Treatment-Related Adverse Events Associated with egfr Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer DOI Creative Commons

Vera Hirsh

Current Oncology, Journal Year: 2011, Volume and Issue: 18(3), P. 126 - 138

Published: June 1, 2011

Non-small-cell lung cancer (nsclc) has the highest prevalence of all types cancer, which is second most common and leading cause cancer-related mortality in Canada. The need for more effective less toxic treatment options nsclc led to development agents targeting epidermal growth factor receptor (egfr)–mediated signalling pathway, such as egfr tyrosine kinase inhibitors (egfr-tkis). Although egfr-tkis are than traditional anti-neoplastic agents, they commonly associated with acneiform-like rash diarrhea. This review summarizes clinical presentation causes egfr-tki–induced diarrhea, presents strategies assessment, monitoring, these adverse effects. Strategies improve management egfr-tki–related events should outcomes, compliance, quality life patients advanced nsclc.

Language: Английский

Citations

127
PD-1 blockade in advanced NSCLC: A focus on pembrolizumab DOI Creative Commons
Solange Peters,

Keith M. Kerr,

Rolf A. Stahel

et al.

Cancer Treatment Reviews, Journal Year: 2017, Volume and Issue: 62, P. 39 - 49

Published: Oct. 23, 2017

Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers and responsible for a large proportion all cancer-related deaths. Current treatment options are inadequate, reflecting substantial unmet clinical need. Increasing knowledge regarding mechanisms genetic aberrations underlying tumor development growth has heralded new era therapy in oncology, moving away from indiscriminate cytotoxic chemotherapy toward more finely focused, targeted medicine. The small-molecule drugs monoclonal antibodies directed specific components dysfunctional molecular or immune pathways, mutated genes to particular types, leading field personalized less toxic options, many which have demonstrated greater efficacy survival benefits than their chemotherapeutic counterparts. Particularly successful examples agents that interfere with programmed death 1 (PD-1) pathway, tumors can hijack avoid surveillance editing. Pembrolizumab, antibody at PD-1 blocks engagement between its ligands, been explored as solid tumors, several studies. use inhibitors such nivolumab pembrolizumab advanced widespread, available 60 countries least following: melanoma, PD-L1-expressing NSCLC, head neck squamous carcinoma, adult pediatric patients refractory classical Hodgkin's lymphoma. This work provides brief overview role (recurrent/metastatic) NSCLC.

Language: Английский

Citations

126
Reducing the toxicity of cancer therapy: recognizing needs, taking action DOI
Charles S. Cleeland, Jeff Allen, Samantha Roberts

et al.

Nature Reviews Clinical Oncology, Journal Year: 2012, Volume and Issue: 9(8), P. 471 - 478

Published: July 3, 2012

Language: Английский

Citations

122
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study DOI Creative Commons
Martin J. van den Bent, Hui Gan, Andrew B. Lassman

et al.

Cancer Chemotherapy and Pharmacology, Journal Year: 2017, Volume and Issue: 80(6), P. 1209 - 1217

Published: Oct. 26, 2017

Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, an antibody-drug conjugate that preferentially binds cells EGFR amplification, internalized and releases potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, efficacy depatux-m monotherapy at recommended Phase 2 dose (RPTD) patients EGFR-amplified, rGBM.

Language: Английский

Citations

120
Mechanisms underlying skin disorders induced by EGFR inhibitors DOI Open Access
Martin Holcmann, Maria Sibilia

Molecular & Cellular Oncology, Journal Year: 2015, Volume and Issue: 2(4), P. e1004969 - e1004969

Published: June 1, 2015

The epidermal growth factor receptor (EGFR) is a tyrosine kinase that frequently mutated or overexpressed in large number of tumors such as carcinomas glioblastoma. Inhibitors EGFR activation have been successfully established for the therapy some cancers and are more being used first later line therapies. Although side effects induced by inhibitors less severe than those observed with classic cytotoxic chemotherapy can usually be handled out-patient care, they may still cause dose reduction discontinuation treatment reduce effectiveness antitumor therapy. mechanisms underlying these cutaneous only partly understood. Important questions, reasons correlation between intensity efficiency inhibitors, remain to answered. Optimized adjuvant strategies accompany anti-EGFR need found optimal therapeutic application improved quality life patients. Here, we summarize current literature on molecular cellular provide evidence keratinocytes probably targets aimed at alleviating skin toxicities.

Language: Английский

Citations

117